Tina Marriott Larson Sells 8,000 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock
Tina Marriott Larson Sells 8,000 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) COO Tina Marriott Larson sold 8,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Thursday, January 26th. The shares were sold at an average price of $8.07, for a total transaction of $64,560.00. Following the sale, the chief operating officer now owns 203,654 shares of the company's stock, valued at $1,643,487.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
遞歸製藥公司(納斯達克代碼：RXRX-GET評級)首席運營官蒂娜·萬豪·拉森在1月26日星期四的一筆交易中出售了8,000股遞歸製藥公司的股票。這些股票以8.07美元的平均價格出售，總成交金額為64,560.00美元。出售後，首席運營官現在擁有203,654股公司股票，價值1,643,487.78美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的，該文件可通過此超鏈接.
Tina Marriott Larson also recently made the following trade(s):
蒂娜·萬豪·拉爾森最近還進行了以下交易：
- On Thursday, December 29th, Tina Marriott Larson sold 8,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.70, for a total transaction of $61,600.00.
- On Thursday, November 17th, Tina Marriott Larson sold 16,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $10.96, for a total transaction of $175,360.00.
- 12月29日，星期四，蒂娜·萬豪·拉爾森出售了8000股遞歸製藥公司的股票。這些股票以7.70美元的平均價格出售，總成交額為61,600.00美元。
- 11月17日，星期四，蒂娜·萬豪·拉爾森出售了1.6萬股遞歸製藥公司的股票。這些股票以10.96美元的平均價格出售，總成交金額為175,360.00美元。
Recursion Pharmaceuticals Stock Up 4.3 %
遞歸製藥類股上漲4.3%
Shares of NASDAQ RXRX opened at $8.54 on Friday. Recursion Pharmaceuticals, Inc. has a 52 week low of $4.92 and a 52 week high of $14.18. The firm's fifty day moving average is $8.41 and its 200 day moving average is $9.77.
上週五，納斯達克RXRX的股價開盤報8.54美元。Recursion PharmPharmticals，Inc.的52周低點為4.92美元，52周高位為14.18美元。該公司的50日移動均線切入位為8.41美元，200日移動均線切入位為9.77美元。
Analysts Set New Price Targets
分析師設定新的價格目標
A number of brokerages have recently weighed in on RXRX. SVB Leerink lowered their price objective on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating for the company in a report on Monday, January 23rd. The Goldman Sachs Group boosted their price objective on shares of Recursion Pharmaceuticals from $8.00 to $9.00 and gave the stock a "neutral" rating in a report on Wednesday, November 9th.
最近，許多券商都加入了RXRX的行列。SVB Leerink在1月23日週一的一份報告中將其對Recursion PharmPharmticals的股票目標價從9.00美元下調至8.00美元，併為該公司設定了“市場表現”評級。在11月9日星期三的一份報告中，高盛夫婦將遞歸製藥的股票目標價從8.00美元上調至9.00美元，並給予該股“中性”評級。
Institutional Inflows and Outflows
機構資金流入和流出
Several hedge funds have recently made changes to their positions in the company. Baillie Gifford & Co. increased its stake in shares of Recursion Pharmaceuticals by 14.9% in the fourth quarter. Baillie Gifford & Co. now owns 24,820,850 shares of the company's stock worth $191,369,000 after buying an additional 3,226,157 shares during the period. Bank of New York Mellon Corp increased its position in Recursion Pharmaceuticals by 26.2% during the 3rd quarter. Bank of New York Mellon Corp now owns 503,941 shares of the company's stock valued at $5,362,000 after purchasing an additional 104,588 shares during the period. Teachers Retirement System of The State of Kentucky purchased a new position in Recursion Pharmaceuticals during the 3rd quarter valued at $1,750,000. Advisory Research Inc. increased its position in Recursion Pharmaceuticals by 56.6% during the 3rd quarter. Advisory Research Inc. now owns 96,803 shares of the company's stock valued at $1,030,000 after purchasing an additional 34,999 shares during the period. Finally, BNP Paribas Arbitrage SNC purchased a new position in Recursion Pharmaceuticals during the 3rd quarter valued at $1,139,000. 63.62% of the stock is owned by hedge funds and other institutional investors.
幾家對衝基金最近對他們在該公司的頭寸進行了調整。Baillie Gifford&Co.在第四季度增持了Recursion PharmPharmticals的股份14.9%。Baillie Gifford&Co.現在持有24,820,850股該公司股票，價值191,369,000美元，在此期間又購買了3,226,157股。紐約梅隆銀行(Bank Of New York Mellon Corp)第三季度將其在Recursion PharmPharmticals的頭寸增加了26.2%。紐約梅隆銀行(Bank Of New York Mellon Corp)目前持有503,941股該公司股票，價值5,362,000美元，在此期間又購買了104,588股。肯塔基州教師退休系統在第三季度購買了一個新的遞歸製藥職位，價值1,750,000美元。諮詢研究公司在第三季度將其在遞歸製藥公司的頭寸增加了56.6%。Consulting Research Inc.在此期間又購買了34,999股，目前持有該公司96,803股股票，價值1,030,000美元。最後，法國巴黎銀行套利SNC在第三季度購買了Recursion PharmPharmticals的新頭寸，價值1,139,000美元。63.62%的股票由對衝基金和其他機構投資者持有。
About Recursion Pharmaceuticals
關於遞歸製藥公司
(Get Rating)
(獲取評級)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis.
遞歸製藥公司是一家臨牀階段的生物技術公司，通過整合跨越生物、化學、自動化、數據科學和工程的技術創新來實現藥物發現的工業化，致力於解碼生物學。該公司開發了REC-994，用於治療腦海綿狀血管畸形的第二階段臨牀試驗；REC-2282，用於治療2型神經纖維瘤病；REC-4881，用於治療家族性腺瘤性息肉病；以及REC-3599，用於治療GM2神經節苷脂增多症，處於第一階段臨牀試驗。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Recursion Pharmaceuticals (RXRX)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
- 免費獲取StockNews.com關於遞歸製藥的研究報告(RXRX)
- 市場回顧周-1/23-1/27
- 為什麼Lucid在一天內飆升了近100%
- 利用這些鐵路股票實現增長和收入
- ASML預計今年芯片需求回升，提振銷售觀點
- KLA公司：在動盪不安的半市場中站穩腳跟
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接受《遞歸藥物日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Recursion PharmPharmticals和相關公司的最新新聞和分析師評級的每日摘要。